摘要
目的探究采用他莫昔芬联合米非司酮治疗围绝经期子宫肌瘤的临床疗效。方法选取2018年4月至2021年4月本院收治的80例围绝经期子宫肌瘤患者作为研究对象,按照随机抽样法分为两组,每组40例。对照组给予米非司酮治疗,观察组在对照组基础上给予他莫昔芬治疗,比较两组临床疗效、不良反应发生情况、治疗前后临床指标[子宫内膜厚度、肌瘤体积、子宫体积、月经失血图评分法(PBAC)]、激素[促卵泡激素(FSH)、促黄体激素(LH)、孕激素(P)、雌二醇(E_(2))]水平。结果观察组治疗总有效率为97.50%,高于对照组的80.00%,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。治疗前,两组子宫内膜厚度、肌瘤体积、子宫体积及PBAC评分比较差异无统计学意义;治疗后,两组子宫内膜厚度薄于治疗前、肌瘤体积、子宫体积均小于治疗前,PBAC评分均低于治疗前,观察组子宫内膜厚度薄于对照组、肌瘤体积、子宫体积均小于对照组,PBAC评分低于对照组,差异有统计学意义(P<0.05)。治疗前,两组FSH、LH、P、E_(2)水平比较差异无统计学意义;治疗后,两组FSH、LH、P、E_(2)水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。结论他莫昔芬联合米非司酮治疗围绝经期子宫肌瘤疗效确切,亦可缩小子宫体积及肌瘤体积,在降低子宫内膜厚度的同时减少月经量,安全性较高,值得临床推广应用。
Objective To explore the clinical efficacy of tamoxifen combined with mifepristone in the treatment of perimenopausal uterine fibroids.Methods A total of 80 patients with perimenopausal uterine fibroids admitted to our hospital fromApril 2018 to April 2021 were selected as the research subjects,and they were divided into two groups according to random sampling method,with 40 cases in each group.The control group was given mifepristone treatment,and the observation group was given tamoxifen treatment based on the control group,the clinical efficacy,occurrence of adverse reactions,and clinical indicators(endometrial thickness,myoma volume,uterine volume,menstrual blood loss graph score[PBAC]),hormone levels(folliclestimulating hormone[FSH],luteinizing hormone[LH],progesterone[P],estradiol[E_(2)])before and after treatment were compared between the two groups.Results The total effective rate in the observation group was 97.50%,which was higher than 80.00%in the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Before treatment,there were no significant differences in endometrial thickness,myoma volume,uterine volume and PBAC score between the two groups;after treatment,endometrial thickness of the two groups were thinner than those before treatment,fibroid volume and uterine volume were smaller than those before treatment,and PBAC scores were lower than those before treatment;endometrial thickness in the observation group was thinner than that in the control group,fibroid volume and uterine volume were smaller than those in the control group,and PBAC score was lower than that in the control group,the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in FSH,LH,P and E_(2) levels between the two groups;after treatment,the levels of FSH,LH,P and E_(2) of the two groups were lower than those before treatment,and observation group was lower than control gr
作者
邓学玲
曾莉
陈艳
DENG Xueling;ZENG Li;CHEN Yan(Department of Obstetrics and Gynecology,the Second People's Hospital ofWuzhong District,Suzhou,Jiangsu,444324,China)
出处
《当代医学》
2023年第10期75-78,共4页
Contemporary Medicine
